

cancers



an Open Access Journal by MDPI

microRNA and Oxidative Drugs in Cancer Therapy and Prevention

Guest Editors:

Prof. Dr. Alberto Izzotti

1. Department of Experimental
Medicine, School of Medicine and
Pharmacy, University of Genoa,
16132 Genoa, Italy
2. Comprehensive Cancer Center
St. Martino Hospital, 16132
Genoa, Italy

Prof. Dr. Ming You

Center for Disease Prevention
Research and Department of
Pharmacology and Toxicology,
Medical College of Wisconsin,
Milwaukee, WI 53226, USA

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editors

Dear Colleagues,


The epigenetic control of gene expression is achieved at the postgenomic level in the cytoplasm by microRNA machinery. MicroRNAs are able to intercept and suppress messenger RNAs encoded by mutated oncogenes, thus blocking the progress, spreading, and recurrences of cancer. Indeed, cancer growth occurs only when microRNA machinery is severely damaged. MicroRNA expression can be restored and modulated by the administration of suitable microRNA mimics.....

The goal of this Special Issue is to focus on the clinical applicability of microRNA and oxidative drugs to cancer therapy and prevention. The issue will analyze the status of experimental knowledge in preclinical experimental models as well as the translatability of the obtained results to the clinics. Attention will be focused on the use of microRNA and oxidative drugs as complimentary approaches to chemo-radiotherapies in cancer therapy to overcome resistance and in cancer prevention to decrease the risk of relapses.



mdpi.com/si/76045

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI